Medtronic Q2 FY2025 Earnings Highlight: Cardiovascular Business Drives Strong Growth

Nov 22, 2024 19:05 CST Updated 19:05

Medtronic

Chronic Disease Medical Device and Therapy Developer

▲ Source of the article: Eshare Medical Device Hub

▲Please indicate the above source at the beginning of the article when reprinting.

As a global leader in the medical technology industry, Medtronic released its fiscal year 2025 second-quarter financial report on November 19. This quarter,MedtronicRevenue and profit performance exceeded expectations, with strong growth achieved across multiple business areas.

Continuous Growth, Exceeding Expectations

Medtronic AchievesTotal revenue of $8.403 billion, a year-on-year increase of 5.3%, representing an organic growth of 5.0%. In terms of global market layout,U.S. market revenue was $4.304 billion, a year-over-year increase of 3.3%; international market revenue was $4.099 billion, a year-over-year increase of 7.0%., showing strong growth momentum in overseas markets.

In terms of profitability, the non-GAAP adjusted earnings per share were $1.26, representing a 1% increase year-over-year. Excluding the impact of exchange rates, the growth rate of adjusted earnings per share reached 8%.

Despite the impact of exchange rate fluctuations, GAAP net income reached $1.27 billion, surging 40% year-over-year.

Diversified Development, Comprehensive Breakthrough

Cardiovascular Business

Cardiovascular Sector$3.102 billionThe revenue has become a highlight of the core business.An increase of 5.6% year-on-year. The following are its main manifestations:

Cardiac Rhythm Management and Heart Failure Solutions: Cardiac rhythm management devices such as the Micra™ leadless pacemaker achieved high double-digit growth, particularly demonstrating strong performance in the minimally invasive field; the ongoing advancement of the Aurora™ EV-ICD (extravascular implantable cardioverter-defibrillator) and the TYRX antibacterial envelope system also contributed to the growth.
Structural Heart and Aortic Business: The structural heart segment benefited from the launch of the Evolut™ FX+ TAVR system in the United States, driving high single-digit growth; the cardiac surgery segment achieved double-digit growth, with the new product Avalus™ Ultra surgical heart valve gaining significant market attention.
Coronary and Peripheral Vascular Treatment: Coronary and peripheral vascular businesses achieved mid-single-digit growth driven by catheters and balloon products. The newly launched Symplicity™ Spyral Renal Denervation Catheter will further enhance the commercial potential of this catheter through the TPT payment policy.

Neuroscience Business

Neuroscience segment shows outstanding performance,Revenue reached $2.451 billion，An increase of 6.7% year-over-year, becoming one of the fastest-growing fields.

Cranial and Spinal Technologies (CST): Driven by the ongoing promotion of the AiBLE™ ecosystem and the strong performance of the ModuLeX™ spinal system, the CST segment achieved high single-digit growth.
Neuromodulation Devices: The deep brain stimulation (DBS) device Percept™ RC, combined with BrainSense™ technology, is leading the market with high double-digit growth. The spinal cord stimulation device Inceptiv™ closed-loop control system has also performed notably well in the U.S. market.
Specialized Therapy (ST): In the neuromodulation business, products targeting stroke maintained mid-single-digit growth; the pelvic health segment also performed robustly due to the continued adoption of the InterStim X™ system.

Medical Surgical Business

Medical Surgical BusinessRevenue of $2.128 billion,An increase of 0.7% year-on-year. Although the growth rate is relatively slow, the performance of some细分fields is worth noting:

Surgical and Endoscopic Techniques (SE): Driven by the efficiency of products such as the LigaSure™ XP Vessel Sealer and ProGrip™ Self-Fixating Mesh, the surgical sector achieved high single-digit quarter-over-quarter growth.
Acute Care & Monitoring (ACM): Strong sales of sensors for the Nellcor™ pulse oximeter, a blood oxygen management product, drove high single-digit growth in this segment.
Surgical Robot Layout: The Hugo™ Robotic-Assisted Surgery System is rapidly advancing through U.S. FDA approval, with the potential to further expand the field of surgical automation in the future.

Diabetes Business

The diabetes sector performed particularly outstandingly,Revenue of $686 million, a year-on-year increase of 11.0%, becoming one of the fastest-growing sectors.

MiniMed™ 780G System: As the world's leading automated insulin management device, the system’s promotion in the U.S. market drove high single-digit growth; low double-digit growth in international markets was primarily attributed to strong demand for CGM (Continuous Glucose Monitoring) accessories.
Simplera™ Sync Sensor: This next-generation sensor has been launched in 16 countries, further enhancing Medtronic's competitiveness in the international market.
R&D Progress: The company has submitted an extended application to the FDA for the MiniMed™ 780G system in type 2 diabetes, gestational, and pediatric indications, with potential approval expected in the first half of 2025.

Technology Leads the Future, Layout for Long-term Development

Innovation-driven R&D serves as a crucial engine for driving business growth and industry leadership. In the second quarter of fiscal year 2025, Medtronic made significant progress in technological innovation and product positioning within high-growth fields, with R&D expenditure reaching$6.97 billion, accounting for 8.3% of total revenue

Innovative Products and Key Breakthroughs

Symplicity™ Spyral Renal Denervation Catheter: As an innovative treatment for hypertension, the catheter has received support from the US Transitional Pass-Through (TPT) policy and will be implemented for payment under US Medicare starting in early 2025. This breakthrough marks Medtronic's global leadership in the field of hypertension management.

Evolut™ FX+ TAVR System: This transcatheter aortic valve replacement system has been successively launched in the U.S. and European markets, gaining widespread recognition for its improved precision and operational convenience, becoming an important innovation in the field of structural heart disease treatment.

Simplera™ Sync Sensor: The new generation of CGM (Continuous Glucose Monitoring) devices launched in the diabetes field has rapidly expanded to 16 international markets with higher patient convenience and accuracy, bringing a brand-new experience to diabetes management.

R&D Pipeline Expansion and Technology Outlook

Surgical Robotics Field: The Hugo™ robotic-assisted surgery system is advancing through the FDA’s “de novo” approval process and has completed a rapid enrollment trial in the United States, laying the foundation for the intelligence and automation of surgical procedures.

Pulsed Field Ablation (PFA) Technology:PulseSelect™ PFA System Receives FDA Approval and is Launched in European and American Markets. This emerging technology demonstrates high efficiency, safety, and precision in treating arrhythmia conditions such as atrial fibrillation.

Artificial Intelligence and Digital Technology: In the field of neuroscience, the company is exploring the potential of adaptive deep brain stimulation (aDBS) technology through its ADAPT-PD clinical trial, with the goal of achieving more personalized treatments for neurological disorders.

Cross-domain Collaboration and Ecosystem Construction

Collaboration with Siemens Healthineers: Jointly promote the Multitom Rax™ imaging system, which integrates with Medtronic's AiBLE™ spinal surgery ecosystem to provide an integrated solution for spinal surgery from imaging to operation.

Collaboration with Abbott's sensors: To further enrich the CGM device portfolio, Medtronic has initiated a collaboration plan with Abbott, combining the technical strengths of the two industry giants to provide diabetes patients with a more comprehensive solution.

Profitability Improvement and Future Guidance Raised

Medtronic Enhances Profitability Through Continuous Optimization of Operational Efficiency:

Gross Margin Improvement: Adjusted Gross Margin Reached65.2%, an increase of 40 basis points year-over-year, reflecting the company's success in pricing strategy and supply chain management.
Enhanced Operational Efficiency: Adjusted Operating Profit Margin24.3%, an increase of 100 basis points year-over-year, thanks to strict cost control and improved efficiency in R&D investment.
Free Cash Flow Growth: As of this quarter, Medtronic's free cash flow year-to-date has reached$10 billion, up nearly 30% year-over-year。

Benefiting from the financial performance this quarter, Medtronic is confident in its outlook for the 2025 fiscal year and has raised its full-year guidance:

Revenue Target: The full-year organic revenue growth expectation has been raised from 4.5%-5.0% to 4.75%-5.0%.
Earnings Per Share: Adjusted Diluted EPS Target Range Raised to $5.44-$5.50.

Source of Materials: Publicly Available Online Information

Note: The above content is for reference only and does not constitute investment advice. The interpretation of official policies in this article represents the views of this platform, and the content is subject to official documents. If any platform reprints this article, it must take responsibility for the content of the article itself and will not be responsible for any impact caused by secondary dissemination after reprinting.

More Cutting-edge and Precise Medical Device DataAll in20Edition 24

"China Medical Device Blue Book"》

Scan the QR code in the image below to purchase.

‍

If you like it, click "Watch" before you go.

EBIT (Earnings Before Interest and Taxes)